文献速递肾移植肾小球疾病

Alport综合征肾移植后的基因型与结局

Genotype and Outcome After Kidney Transplantation in Alport Syndrome.
PubMed 文献 · Kidney Int Rep · 2018-02-02

该研究纳入73例已鉴定突变的Alport综合征患者共93个肾移植,评估突变严重程度对移植后患者及移植物存活和抗GBM肾炎的影响。结果显示严重突变不影响患者和移植物存活,移植后新发抗GBM肾炎仅1.4%。

要点

  • 严重突变不影响Alport综合征移植后患者及移植物存活。
  • 移植后新发抗GBM肾炎发生率低于既往报告,仅1.4%。
  • 抗GBM肾炎多见于严重COL4A5突变男性,可致移植物丢失。

核心结论

  • 严重突变虽影响Alport综合征严重程度,但不影响移植后患者和移植物存活。

研究设计与样本

  • 回顾性纳入1971至2014年间73例已鉴定突变的Alport综合征患者共93个肾移植。
  • 41例为严重突变,32例为非严重突变;突变基因包括COL4A5、COL4A3、COL4A4及复合杂合。

主要发现

  • 严重与非严重突变患者5年生存率89% vs 84%,10、15、20年均为83% vs 75%,P=0.46。
  • 严重与非严重突变移植物5年存活率77% vs 63%,10年60% vs 55%,15年55% vs 55%,20年55% vs 50%,P=0.65。
  • 1例严重COL4A5突变男性移植后6年发生临床显著抗GBM肾炎,后续移植物复发并两次导致移植物丢失。

关键数值与推荐

  • 移植后新发抗GBM肾炎发生于1.4%的Alport综合征患者和2%的COL4A5突变男性。

临床怎么用

  • Alport综合征肾移植后结局总体良好,严重突变并非移植禁忌。
  • 对严重COL4A5突变男性移植后需警惕抗GBM肾炎,但发生率低于既往报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Alport syndrome (AS) is caused by mutations in α3/α4/α5 (IV) collagen genes, the severity of which determine the progression of AS. Posttransplantation outcome is good, although anti-glomerular basement membrane (anti-GBM) glomerulonephritis occurs in 3% to 5% of recipients, clustering in patients with a severe mutation. We assessed whether the severity of the underlying AS mutation affects graft and patients outcome after transplantation, including the occurrence of anti-GBM nephritis. METHODS: We included 73 AS patients with an identified mutation (COL4A5, 57 patients; COL4A3, 9 patients; COL4A4, 6 patients; heterozygous composite COL4A3 and A4, 1 patient) who underwent transplantation between 1971 and 2014 and who had received a total of 93 kidney grafts. RESULTS: In all, 41 patients had a severe mutation (COL4A5, 30 patients; COL4A3, 6 patients; COL4A4, 5 patients), and 32 had a nonsevere mutation (COL4A5, 27 patients; COL4A3, 4 patients; COL4A4, 1 patient). Patient survival was similar in patients with severe and nonsevere mutations (89% vs. 84% at 5 years, 83% vs. 75% at 10, 15, and 20 years; P = 0.46). Graft survival was not affected by the severity of mutation (77% vs. 63% at 5 years, 60% vs. 55% at 10 years, 55% vs. 55% at 15 years, and 55% vs. 50% at 20 years; P = 0.65). Clinically significant anti-GBM glomerulonephritis occurred in 1 male patient with severe COL4A5 mutation 6 years after transplantation recurred in a subsequent graft, leading twice to graft loss. CONCLUSION: Although severe mutations affect the severity of AS, they do not have an impact on patient and graft survival after transplantation. De novo anti-GBM nephritis after transplantation was less frequent than previously reported, occurring in only 1.4% of AS patients, and in 2% of males with COL4A5 mutation.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Gillion V, Dahan K, Cosyns JP, et al. Genotype and Outcome After Kidney Transplantation in Alport Syndrome. Kidney Int Rep. 2018. PMID: 29854973. doi:10.1016/j.ekir.2018.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。